Efficacy and Cost-Efficacy of Biologic Therapies for Moderate to Severe Psoriasis: A Meta-Analysis and Cost-Efficacy Analysis Using the Intention-to-Treat Principle

Table 2

Incremental efficacy and cost-efficacy based on at least 75% reduction in the Psoriasis Area and Severity Index score.

Biologics	Pooled incremental efficacy			6-month incremental cost-effectiveness ratio
	Base case	Best case	Worst case	Base case	Best case	Worst case
Etanercept	55%	72%	38%	$32,643	$24,936	$47,246
Adalimumab	63%	67%	59%	$21,315	$20,043	$22,760
Infliximab	71%	76%	67%	$27,782	$25,954	$29,440
Ustekinumab 45 mg	67%	73%	62%	$25,055	$22,996	$27,075
Ustekinumab 90 mg	72%	75%	68%	$46,630	$44,765	$49,373